Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ZBIO ProShares UltraPro Short Nasdaq Biotechnology (ZBIO) Price, Holdings, & News Add Compare Share Share Stock Analysis Stock AnalysisOptions ChainTrends About ProShares UltraPro Short Nasdaq Biotechnology (NASDAQ:ZBIO) 30 days 90 days 365 days Advanced Chart Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Get ZBIO alerts:Sign Up Key Stats Today's Range$9.31▼$10.3850-Day Range$10.02▼$10.0952-Week Range$8.28▼$18.64Volume3.63 million shsAverage Volume364,207 shsMarket Capitalization$418.32 millionAssets Under Management$2.85 millionDividend YieldN/ANet Expense Ratio0.95%Aggregate RatingN/A ETF OverviewZenas BioPharma Inc. is a clinical-stage global biopharmaceutical company. It involved in the development and commercialization of transformative immunology-based therapies for patients in need. The company's lead product candidate includes obexelimab and Fc?RIIb. Zenas BioPharma Inc. is based in WALTHAM, Mass.Read More… ProShares UltraPro Short Nasdaq Biotechnology ExpensesTypeZBIOHealth Care ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.75%0.57%0.55%0.50%0.52%Other Expenses1.02%0.30%0.49%0.41%0.53%Total Expense1.77%0.70%0.71%0.64%0.71%Fee Waiver-0.82%-0.45%-0.51%-0.31%-0.56%Net Expense0.95%0.61%0.61%0.57%0.59% Receive ZBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ProShares UltraPro Short Nasdaq Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address ZBIO ETF News HeadlinesZenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate UpdatesNovember 12, 2024 | globenewswire.comZenas BioPharma Completes Targeted Enrollment of the Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)November 12, 2024 | globenewswire.comYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average APY on savings is just 0.58%, but you can get up to 5.0% APY online with these accounts.December 22, 2024 | MyBankTracker (Ad)Zenas BioPharma to Participate in Upcoming Healthcare Investor ConferencesNovember 7, 2024 | globenewswire.comLast Week's 3 Biotech IPOs Prompt Huge Insider BuyingSeptember 22, 2024 | 247wallst.comZenas BioPharma Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares in Initial Public OfferingSeptember 19, 2024 | globenewswire.comSee More Headlines ZBIO ETF - Frequently Asked Questions How were ProShares UltraPro Short Nasdaq Biotechnology's earnings last quarter? ProShares UltraPro Short Nasdaq Biotechnology (NASDAQ:ZBIO) announced its quarterly earnings data on Tuesday, November, 12th. The company reported ($5.02) EPS for the quarter, topping analysts' consensus estimates of ($13.00) by $7.98. When did ProShares UltraPro Short Nasdaq Biotechnology IPO? ProShares UltraPro Short Nasdaq Biotechnology (ZBIO) raised $225 million in an initial public offering on Friday, September 13th 2024. The company issued 13,235,294 shares at a price of $17.00 per share. When did the company's quiet period expire? ProShares UltraPro Short Nasdaq Biotechnology's quiet period expired on Wednesday, October 23rd. ProShares UltraPro Short Nasdaq Biotechnology had issued 13,235,294 shares in its IPO on September 13th. The total size of the offering was $224,999,998 based on an initial share price of $17.00. During the company's quiet period, underwriters and any insiders that worked on the IPO were prevented from issuing any earnings forecasts or research reports for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company. What other stocks do shareholders of ProShares UltraPro Short Nasdaq Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that ProShares UltraPro Short Nasdaq Biotechnology investors own include AST SpaceMobile (ASTS), Tempus AI (TEM), Trade Desk (TTD), Advanced Micro Devices (AMD), BioSig Technologies (BSGM), Ford Motor (F) and Genius Sports (GENI). Fund Details IssuerProShares Fund NameProShares UltraPro Short Nasdaq Biotechnology Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:ZBIO Inception Date6/22/2015 Fund ManagerMichael Neches, Tarak Dave Webwww.zenasbio.com Phone857-271-2954Fund Focus Asset ClassEquity BenchmarkNASDAQ Biotechnology Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings0 Fund Statistics Assets Under Management$2.85 million Average Daily Volume$25,501.70 Discount/Premium0.00% Administrator, Advisor and Custodian AdministratorJ.P. Morgan Investor Services Co. AdvisorProShare Advisors LLC CustodianJPMorgan Chase Bank, N.A. DistributorSEI Investments Distribution Co. Transfer AgentJPMorgan Chase Bank, N.A. TrusteeN/A Lead Market MakerVirtu Financial Miscellaneous Outstanding Shares41,790,000BetaN/A 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report This page (NASDAQ:ZBIO) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProShares UltraPro Short Nasdaq Biotechnology Please log in to your account or sign up in order to add this asset to your watchlist. Share ProShares UltraPro Short Nasdaq Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
